search-icon
AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Tenable acquires Sam Altman-backed Apex for over $105 million to boost AI security
2
Combat-ready and camera-eyed: The X-Intra drone joins Israel’s arsenal
3
Buildots raises $45M at $300M valuation to modernize global construction with AI
4
Guardicore founders raise $32 million for new stealth cyber-AI startup
5
Israel’s SMARTSHOOTER lands $13M U.S. Army contract for advanced fire control systems
More news Buzzmore

Gilead Sciences

5 stories about Gilead Sciences
יוהן אלבז

Investments are flowing into synthetic biology - the red-hot field that will change the world

28.07.21|Sophie Shulman
Synthetic biology seemed like science fiction until the arrival of the coronavirus vaccines. But now the money has begun to flow and companies are revealing remarkable inventions: from bacteria that will attack tumors to shoes made of cobwebs
משרדי בורסת נאסד"ק ב ניו יורק

ForeBio is on its way to Nasdaq at a $500 million valuation

01.03.21|Tzally Greenberg
The company aims to raise $100 million in an April IPO, while Pontifax and OrbiMed who previously invested $21 million for a 12.5% stake in ForeBio’s shares are expected to make a $120 million profit
מייסד קייט פארמה אריה בלדגרין

Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company

10.12.17|Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
default image

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
מוסף שבועי 14.9.17 פרופ' גידי גרוס

Kite Pharma Sale Triggers Scientist Quarrel

02.10.17|Zohar Shahar Levy
Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur
ProfilesEngineServlet?at=39&mi=10&pt=18&dpi=1243103233&pai=cTech&dpn=4409&mt=1